Abstract Respiratory viral diseases are a leading cause of mortality in humans. They have proven to drive pandemic risk due to their complex transmission factors and viral evolution. However, the slow production of effective antiviral drugs and vaccines allows for outbreaks of these diseases, emphasizing a critical need for refined antiviral therapeutics. The delivery of exosomes, a naturally secreted extracellular vesicle, yields therapeutic effects for a variety of diseases, including viral infection. Exosomes and viruses utilize similar endosomal sorting pathways and mechanisms, providing exosomes with the potential to serve as a therapeutic that can target, bind, and suppress cellular uptake of various viruses including the novel severe acute respiratory syndrome coronavirus 2. Here, we review the relationship between exosomes and respiratory viruses, describe potential exosome therapeutics for viral infections, and summarize progress toward clinical translation for lung‐derived exosome therapeutics.

Kristen D. Popowski

Phuong‐Uyen C. Dinh

Arianna George

Halle Lutz

Ke Cheng

View

VIEW

Exosome therapeutics for COVID‐19 and respiratory viruses

The relationship between exosomes and respiratory viruses is reviewed, potential exosome therapeutics for viral infections are described, and progress toward clinical translation for lung‐derived exosomal therapeutics is summarized.

Category	Quartile
医学	4
医学, 材料科学生物材料	4
医学, 纳米科技	4

Exosome therapeutics for COVID‐19 and respiratory viruses

ivySCI AI Smartly Parses PDF, Answers Researchers' Questions, and Helps You Understand Papers in Seconds

Journal Info

Category	Quartile
NANOSCIENCE & NANOTECHNOLOGY	1